The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis
Abstract
Objective To investigate treatment outcomes, hearing outcomes, and adverse effects of rituximab (RTX) for intractable otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV). Methods Twenty-three patients who met the criteria proposed by the OMAAV study group were included. RTX was used for patients who had difficulty achieving induction of remission using glucocorticoids (GC) and intravenous cyclophosphamide...
Paper Details
Title
The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis
Published Date
Feb 1, 2019
Journal
Volume
46
Issue
1
Pages
38 - 42
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History